As we begin a new academic year, it is important to acknowledge and celebrate the recent promotions of our faculty and research scientists. We hope that you, like all of us on departmental promotions committees, the Dean’s Office, and the APT Committee, are also amazed at the breadth and depth of accomplishments in teaching, clinical care, research, scholarship, and engagement of our academic community.

In a year that has provided its share of challenges for us all, we hope you stop to reflect and appreciate what your colleagues have done and to congratulate them all for their contributions.

Duane, Leslie, Faith and Alicia
Faculty

Faculty Promotions in
Academic Year 2019-2020
William A. Abdu, MD, MS
Promotion to Professor of Orthopaedics and of Health Policy & Clinical Practice
Academic Medical System Line

In addition to being a dedicated teacher of medical students, residents and faculty, Dr. Abdu provides clinical and surgical care for patients with degenerative, traumatic and acquired conditions of the cervical, thoracic and lumbar spine. From 2003-2014, he served as the Medical Director of the Dartmouth Spine Center, a nationally recognized model for value-based spine care deliver and was integrally involved with the Spine Outcomes Research Trial (SPORT), outcomes from which have changed spine care deliver and surgery nationally and internationally.
Dr. Andrew is an inter-disciplinary scientist in the fields of population science, toxicology, and statistical analysis. Her research is focused on the molecular epidemiology of contaminants in populations and on increasing our understanding of molecular perturbations that then translate back to population health.
Kelly A. Aschbrenner, PhD
Promotion to Associate Professor of Psychiatry
and of Health Policy & Clinical Practice
Academic Medical System Line

Dr. Aschbrenner is a mental health services researcher and implementation scientist whose research focuses on developing, evaluating, and implementing evidence-based interventions to promote health in vulnerable and underserved populations. She leads intervention research evaluating lifestyle interventions to address cardiovascular risk in young adults living with serious mental illness. Her implementation research focuses on strategies for adapting evidenced-based interventions to fit in routine clinical settings while maintaining their effectiveness. She was recently appointed Director of Research at New Hampshire Hospital, the state’s psychiatric intensive unit, where she will build capacity for hospital-based and community research and research mentoring.
Dr. Broglio has had a long-standing commitment to providing care to those who face death and serious debilitating pain. Her career began by efforts focused on how to best provide care to patients with HIV/AIDS, to the science and practice of pain management and addiction, to palliative care. She has been at the forefront of scholarly work and programmatic design in hospice/palliative care at a time when it was a barely recognized field and has since become nationally recognized as a leader. She has continued to advance these initiatives through clinical research related to substance abuse, palliative medicine, and augmenting interprofessional care.
Dr. Brown is an interdisciplinary scientist whose work focuses on predictive analytics, biomedical informatics, and implementation science, with an emphasis on cardiovascular disorders and acute kidney injury/disease. He has employed natural language processing and externally validated machine learning in the development of implementation tools in these areas and has identified novel biomarkers as hallmarks of these diseases/disorders which also facilitate prediction.
Dr. Butterly is a gastroenterologist whose professional mission is the prevention of colorectal cancer (CRC) through optimization of screening. She played a foundational role in establishing the New Hampshire Colonoscopy Registry (NHCR); NHCR investigations have directly contributed to the national guidelines for CRC screening and surveillance. She also leads the CDC-funded New Hampshire CRC Screening Program, which has contributed to New Hampshire having one of the highest rates of CRC screening in the U.S. Dr. Butterly served on the Steering Committee of the National Colorectal Cancer Roundtable, which created and implemented the “80% by 2018” initiative, now known as as one of the most successful public health initiatives in the U.S. Widely recognized for both her research and public health efforts, Dr. Butterly continues to focus on the compelling national goal of decreasing CRC through screening.
Michael Calderwood, MD, MPH
Promotion to Associate Professor of Medicine
Academic Medical System Line

Dr. Calderwood is the Associate Chief Quality Officer at Dartmouth-Hitchcock Medical Center, the Regional Hospital Epidemiologist for the Dartmouth-Hitchcock Health System, and the Medical Co-Director of the Collaborative Healthcare-Associated Infection Prevention Team. His interests focus on hospital epidemiology, infection prevention, antimicrobial stewardship, and patient safety. He is actively involved in quality improvement work in these areas, and he is a member of multiple state and national committees focused on developing education, research, and policies to improve health outcomes. In addition, he is a well-recognized teacher in multiple courses at the medical school and in the Internal Medicine residency and Infectious Diseases fellowship programs.
As chief of the Section of Dermatology, Dr. Chapman has developed a vibrant section involved in clinical care and research. He has championed the non-surgical treatment of melanoma in situ and is currently involved in translational research with the Thayer School of Engineering in the area of photodynamic therapy. Administratively, he is the Medical Director of Supply Chain for the DH-H system and recently became the inaugural Chair of the newly formed Department of Dermatology.
Carrie H. Colla, PhD
Promotion to Professor of Health Policy & Clinical Practice with tenure

Dr. Colla is a health economist and health services researcher specializing in the effects of payment, care delivery, and related health policies on the quality and cost of health care in the United States. In particular, her work has focused on health systems and how they respond to changing payment policies. She uses mixed method analyses to look at large health care utilization data sets to assess how policies change both the costs and quality of care, especially as this related to low-value care and the efficacy of Accountable Care Organizations in serving minority populations.
The overall goal of Dr. Cramer’s research program is to define the pathogenesis and disease progression mechanisms of the spectrum of human diseases caused by the filamentous fungus Aspergillus fumigatus. Understanding these mechanisms is expected to lead to new therapeutic strategies and treatments for these too often lethal diseases. In particular, his research focuses on understanding how fungal physiology at the site of infection in patients impacts the efficacy of antifungal drug treatments and ultimately infection outcome. His laboratory has pioneered studies on the impact of oxygen on fungal pathogenesis mechanisms and are currently working on developing novel small molecule therapies that target these fungal infection site specific mechanisms of pathogenesis.
Dr. Feero is a dedicated family medicine practitioner and committed GME preceptor who has provided critical leadership to the Office of the Director of the National Human Genome Research Institute, and has shaped the national discourse on human genetics in medical practice, including development and wide dissemination of national standards for family health history and genomic test data in electronic records, through this former advisory role to the Director and his long-standing ongoing commitments to the Roundtable on Genomics and Precision Health of the National Academies and through his editorial role at JAMA.
Dr. Foster’s work focuses on the quality improvement, safety, and health systems science, and value of health care; primarily the realm of education, including Graduate and Undergraduate Medical Education, TDI Master’s programs interprofessional programs. She is nationally known for the establishment of the Leadership Preventive Medicine Residency at Dartmouth, which has been highly successful.
Dr. Friedman’s career has been focused on Graduate Medical Education (GME) in the Internal Medicine Residency with a focus on GME Residency Administration and Leadership, Association of Program Directors in Internal Medicine/Alliance of Academic Internal Medicine (APDIM / AAIM), and Technology / Computing solutions to common problems.
Dr. Goodney is a vascular surgeon (with practices at both White River Junction VA and Dartmouth-Hitchcock) and Co-Director of the VA Outcomes Group, with a focus on both open and endovascular procedures for patients with vascular disease. He leads efforts for critical limb ischemia issues, especially in patients needing revisional care. And he also helps lead trans-carotid arterial revascularization (a novel technique in carotid surgery) and has an active role in D-H's aortic surgery program, especially in complex aortic disease. In addition to his clinical work, he is a health services researcher. His research focuses on evaluating how to best guide surgical treatments that are aligned with patient preferences and on identifying variation in the use of vascular surgery procedures and associated outcomes. He is widely recognized for both his clinical expertise and his contributions to research.
Dr. Hassanpour’s research focuses on the development of methodologies to convert largely unstructured medical information (such as clinical notes and medical images) into quantifiable and actionable formats, fostering precision healthcare. He uses approaches highly valued in academic research as well as in the private sector, such as natural language processing and deep machine learning, toward these goals.
Eric R. Henderson, MD
Promotion to Associate Professor of Orthopaedics
Academic Medical System Line

Dr. Henderson’s clinical and research practice focus on musculoskeletal oncology surgery, with particular focus on the surgical treatment, including research and dissemination of novel surgical therapies for bone and soft tissue cancers, and outcomes of patients following bone cancer surgery. He is a cofounder of the national Musculoskeletal Tumor Registry, is known internationally for creating a novel classification system to facilitate comparison of outcomes following failure of limb salvage after reconstructive surgery for bone tumors, and is currently leading work to apply fluorescence guidance to improve the safety and effectiveness of surgery.
Dr. Hoen’s major research focus is to discover the distributions and determinants of disease risk, including cystic fibrosis, colon cancer, Lyme disease, in utero exposure to toxins on postnatal health, maternal diet/delivery method and its effect on infant microbiome. To this end, she has used broad, interdisciplinary approaches to assess complex interactions between humans and the microbial world in solving population health challenges.
Dr. Lanter’s clinical expertise is in the area of Emergency Medicine. Aside from her clinical expertise, her strength and passion are in the teaching and mentoring of undergraduate and graduate medical students. She has devoted much of her medical career to program development and improving the processes and systems in which she works, with an eye on enhancing the care of patients with complex medical needs.
Joel A. Lefferts, PhD
Promotion to Associate Professor of Pathology & Laboratory Medicine
Academic Medical System Line

Dr. Lefferts’s primary focus has been his leadership in the development of programs that bring innovative and highly sophisticated molecular diagnostics to bear on clinical decision-making in ways that improve the value of health care. His efforts have advanced both the clinical and research efforts of the Molecular Pathology Laboratory and the Department of Pathology and Laboratory Medicine through mentoring and training the next generation of academic molecular pathologists.
Dr. Moseley is a cell biologist, studying cell growth as it relates to cell division, addressing questions related to how cells ‘know’ when to divide including mechanisms (e.g., cytokinesis) regulating how they physically separate from each other after division. This is pertinent fundamental knowledge relating to many diseases, including cancer. Defects in both cell cycle progression and cytokinesis lead to a number of human diseases including cancer.
Dr. Nett is a dedicated educator and a strong advocate for evidenced-based care practices in the field of Pediatric Critical Care Medicine (PCCM). She has been extremely active and deeply involved in leadership of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, which has become the preeminent multicenter clinical research collaborative in PCCM, with more than 70 units across North America. She has been a mentor to a full generation of trainees who themselves have graduated to make accomplishments in academic medicine and developed and continues to lead the Scholarly Activity Curriculum for the pediatric residency.
Dr. Nigriny is an accomplished plastic and reconstructive surgeon who has significant experience and expertise in advanced micro-surgical procedures conducted by few others in the U.S. or around the world. He is very active in Graduate Medical Education teaching, in expanding the scope of the Plastic and Reconstructive Surgery Program by furtherance of novel procedures, and in assessing and augmenting the efficiency of the section through telemedicine and cost analysis. Dr. Nigriny has helped spearhead the development of a comprehensive Transgender Medicine and Surgery Center at DHMC. He has also served as the chairman of the Biennial Tanzer Symposium at Dartmouth for the last 6 years.
Dr. Oliver is a healthcare improvement and implementation scientist, educator, and board-certified family and psychiatric nurse practitioner. His work focuses on applied healthcare improvement science research with an emphasis on complex and costly chronic illnesses, coproduction, learning health systems, and shared decision making.
Dr. Onega’s research program is primarily focused on cancer control from a variety of perspectives, including interventions, population-based data systems, comparative effectiveness, primary care networks, rural influences on healthcare, and policy. The most significant domains of her research program and scientific contributions are centered around: 1) cancer early detection; (2) cancer care delivery: access and outcomes; and 3) geospatial factors in population health.
Deborah L. Ornstein, MD
Promotion to Professor of Pathology & Laboratory Medicine and of Medicine
Academic Medical System Line

The primary focus of Dr. Ornstein’s work has been the advancement of the Hemophilia Center at Dartmouth-Hitchcock to a comprehensive Hemophilia and Thrombosis Center (Dartmouth-Hitchcock is now one of the highest recruiting centers per capita for the American Thrombosis and Hemostasis Network), resulting in enhanced patient care, new teaching opportunities, and a number of clinical trials. She also led therapeutic guideline development at Dartmouth-Hitchcock for thromboprophylaxis.
Dr. Pais’s primary interest is in kidney stones—linking together his clinical programmatic development, research, and teaching. He developed the Multidisciplinary Metabolic Stone Clinic, which is a collaborative effort between urology, nephrology, and dieticians and a founding member of the endourologic disease group -EDGE-, a multi-institutional research collaborative. Through this collaborative, Dr. Pais has participated in the design, implementation, and analysis of a number of randomized clinical trials as well as observational studies.
Dr. Pinto-Powell is an active clinician whose academic career has focused on medical education, mentorship, and leadership in both the Undergraduate and Graduate Medical Education curricula. She has developed curricula, including a web-based series of cases for the Inpatient Medicine Core Clerkship (which is used nationally) and she has created innovative programs in the On-Doctoring course including a SIM clinic for teaching clinical skills and establishment of a Patient Bank and a Community Partner Program. Dr. Pinto-Powell is also currently the Associate Dean for Admissions at Geisel and Vice Chair of Clinical Medicine in the Department of Medicine at DHMC while maintaining a large panel of patients. Her specific interests are in the areas of Clinical Reasoning, professionalism and patient bias.
Dr. Pioli’s research is focused on identifying the molecular mechanisms that regulate pathological macrophage (key mediators of tissue homeostasis and immune surveillance, mobilizing immune activation in response to microbial invasion and promoting wound healing to repair damaged tissue) activation, with the ultimate goal of redirecting this activation for therapeutic benefit in the treatment of chronic inflammation, fibrosis, and pathology.
Dr. Pratt’s expertise is in enhancing the functioning and quality of life of people who are challenged by serious mental illness (SMI), improving the quality of clinical care offered by treatment providers, and performing research that positively impacts the field of mental health. She has developed and evaluated interventions focused on improving health, fitness, psychosocial skills, illness self-management skills in the vulnerable population of people with SMI. The interventions she has devised have enhanced the lives of people living with SMI, augmented the skills and quality of care provided by clinicians working with this population, and trained a workforce of researchers dedicated to the mission of creating an ever-growing base of knowledge about best practices for people with SMI.
Phillip E. Schaner, MD
Promotion to Associate Professor of Medicine
Academic Medical System Line

Dr. Schaner is a radiation oncologist whose work focuses on radiotherapy for head and neck cancers, in addition to treating skin, thyroid, and lung malignancies. His research expertise involves the interaction of hypoxia and the sensitivity of squamous cancers to radiotherapy.
Florian R. Schroeck is a board-certified urologist sub-specializing in urologic cancer care. His research focuses on evaluating and improving the quality of care for patients with urologic cancers. Schroeck’s interest in quality of cancer care originated from the finding that patients with prostate cancer who underwent robotic versus the more traditional open surgery experienced more frequent regret of their treatment choice. Schroeck’s research aims to get the right care to every cancer patient. Recently, he has combined administrative and pathology data to understand current patterns of bladder cancer surveillance care within the Department of Veterans Affairs. He has also used qualitative research methods to understand how patients perceive being “under cancer surveillance”. Currently, he is leading a six site study using implementation science methods to improve bladder cancer care within the Department of Veterans Affairs. The goal is to make it easier for physicians, nurses, and other health workers to get the right care to every patient. Schroeck has published more than 50 manuscripts and received several national research awards. He is section chief of urology at the White River Junction VA Medical Center and a core faculty member of the VA Outcomes Group.
Dr. Shiner is a physician and researcher with focus on suicide prevention and posttraumatic stress disorder (PTSD). He has been a research mentor for multiple fellows, helping many to select a research career. In his PTSD research, he developed a natural language processing algorithm to automate analysis of psychotherapy notes, and his work studying suicide data after discharge from the VA lead to tighter follow-up for mental health patients following irregular discharge. His contribution to providing advance access to mental healthcare services has become a national model for the VA system.
Dr. Stone is active clinically at DHMC and at the VAMC where he serves as Chief of the Section of Vascular Surgery. He is also the Program Director of the Integrated Residency and Fellowship training programs in Vascular and Endovascular Surgery, one of the most highly sought after such training programs nationally. His research has focused on protamine use during carotid endarterectomy and the bleeding potential associated with perioperative antiplatelet management and his work on the costs of aortic stent grafts led to national quality improvement in endovascular aneurysm repair delivery.
Dr. Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, a section chief of Laboratory Medicine, is among the top professionals in the field of transfusion medicine and is renowned, both nationally and internationally, for his work in apheresis, cellular therapy and transfusion medicine. Through his work, the linking of American Society for Apheresis (ASFA) treatment categories and the GRADE system now has worldwide acceptance, resulting in a significant decrease in the inappropriate usage of this technology. He serves as the Program Director of the Transfusion Medicine Fellowship Program. He has served as President of AABB and American Society for Apheresis. Currently, he chairs the BEST Collaborative, an international collaborative group of transfusion medicine professionals.
Elizabeth A. Talbot, MD
Promotion to Professor of Medicine
Academic Medical System Line

Dr. Talbot’s area of expertise is in infectious disease (she is certified in many disciplines including Internal Medicine, Infectious Disease, Travel Medicine, and Tropical Medicine). Her research and clinical efforts are national and global in scope and have focused on the protection from and control and management of emerging infectious diseases and epidemic tuberculosis.
A major initiative at Geisel has been to increase and acknowledge the cohort of Research Scientists who make essential contributions to our academic missions. Following on recommendations of a highly engaged and informed task force comprising Research Scientists from across campus, as well as valuable input from Steve Leach and the administration at NCCC, Geisel redefined criteria for advancement in this Non-Faculty Academic Line. In addition to faculty promoted this past year, we want recognize our Research Scientists who have been recently promoted in recognition for all that they do in support of our research and teaching missions.
Dr. Arias-Pulido’s research studies focus on development of appropriate mouse models to translate findings from the lab into the clinic. One of his research areas targets repurposing of current FDA-approved oncology drugs as novel therapeutic agents to treat inflammatory breast cancer, the deadliest form of breast cancer, using patient-derived xenograft models.
Andrea M. Austin, PhD
Promotion to Senior Research Scientist in Health Policy & Clinical Practice

Dr. Austin has led work looking at racial disparities in physician and health systems networks. She has led efforts to examine the impact of social networks on quality of life and care coordination and has provided statistical analytic and claims database expertise across multiple teams at TDI.
Dr. Chang’s work identified the first gene that encodes ACAT1 (Acyl CoA:cholesterol acyltransferases, or ACATs, which are cholesterol storage enzymes that play key roles in cellular cholesterol homeostasis), purified the ACAT1 protein to homogeneity, and helped bring ACAT research into the molecular era. With her long-time collaborator, T.Y. Chang, she mentors students and postdoctoral fellows and plays an active role in demonstrating that ACAT1 is a potential therapeutic target for several human diseases, including Alzheimer’s disease, atherosclerosis, and diet-induced obesity.
Diagnostic precision is pivotal to therapeutic stratification in a malignant disease. Following the current National Comprehensive Cancer Network guidelines, pancreatic ductal adenocarcinoma patients with limited local disease and with no detectable metastasis typically have their primary tumor surgically resected and are then put on adjuvant chemotherapy. However, almost half of these resected cases come back to clinic within a year of surgery with a relapsed disease, despite complete removal of the tumor (R0 resection) and completed course of the adjuvant chemotherapy. Dr. Dhara has been pursuing epigenetics to predict this early recurrence, and to better stratify them at the time of diagnosis. We have invented a novel microarray technology that we termed “ATAC-array” — the only microarray that reads chromatin accessibility. It is a cheaper, faster and robust technology, suitable for clinical diagnostics to guide individualized therapy in PDAC and potentially other malignant diseases.
Kristina M. Godek, PhD
Promotion to Principal Research Scientist in Biochemistry & Cell Biology

Following on her promotion to Senior Research Scientist in 2018, Dr. Godek was recently recognized again by promotion to Principal Research Scientist for her work on aneuploidy, an abnormal number of chromosomes, which is the leading cause of pregnancy miscarriages and birth defects in humans. Her research focuses on understanding the causes and consequences of aneuploidy in human embryonic cells with the goal of developing strategies to prevent aneuploidy and improve the success of reproductive and regenerative medicine therapies.
Dr. Kolling serves as Co-Director of the Genomics and Molecular Biology Shared Resource as well as Co-PI of the Single Cell Genomics Core, part of the Center for Quantitative Biology COBRE. His goal is to make cutting-edge genomics instrumentation and expertise accessible to researchers at Dartmouth and beyond.
Working with extremely large datasets, Dr. Martinez Camblor uses non-parametric time-to-event techniques and statistical regression models, including Cox regression models, to study diagnostic and prognosis problems, as well as the efficacy of medical treatments. The results of his research help inform healthcare providers regarding the effectiveness of medical treatments.
Sharon O'Connor, MBA, MS
Promotion to Senior Research Scientist in Health Policy & Clinical Practice

Through her role at the Center for Program Design and Evaluation (CPDE), Ms. O’Connor has played a key role in writing proposals that have led to the success of obtaining numerous large grants at Dartmouth, and is also the lead evaluator responsible for the design, implementation, and interpretation of evaluative work on those projects. She has also played a key role in extending the impact of CPDE regionally and nationally through her involvement in the INBRE (IDeA program) awards in Maine, Vermont, Delaware, New Hampshire and Rhode Island.
Dr. Channon Smith has served as the Director of the NCCC Immune Monitoring and Flow Cytometry Shared Resource, which were merged in 2010 to form DartLab. Her oversight of these key core services has for decades advanced research efforts of both basic and clinical scientists across Dartmouth and been foundational to many successes with regard to publications and funding.
Meagan E. Stabler, PhD
Promotion to Senior Research Scientist in Epidemiology

Dr. Meagan Stabler collaborates with Dr. Jeremiah Brown (PI) on three NIH R01 projects: IMPROVE-AKI clustered-randomized trial (Co-I) and two predictive analytic grants, Biomarker and AMI NLP. Dr. Stabler seeks external research funding, mentors trainees, and is engaged in the design, analysis and publication of independent research related to cardiovascular and maternal and child health.
Craig R. Tomlinson, PhD
Promotion to Senior Research Scientist in Norris Cotton Cancer Center

Dr. Tomlinson’s research interests are in regard to the role of the aryl hydrocarbon receptor in obesity. He is also the Norris Cotton Cancer Associate Director of shared resources and the Director of the genomics and molecular biology shared resource.
Dr. Verissimo serves as lead scientist and manager of the COBRE Center for Biomolecular Targeting (bioMT) Scientific Core Facilities (MTC and MIIC), which supports the research programs of more than 50 labs within the Dartmouth community. She provides expertise, training opportunities and mentoring to investigators and directs the implementation of an integrated pipeline for production of a wide spectrum of recombinant proteins and investigating biomolecular interactions. Dr. Verissimo is also responsible for the strategic advancement of the cores as institutional and regional resources strengthening the impact of bioMT.